It is definitely a strong contender.

Arbutus Biopharma and Genevant Sciences have filed multiple patent infringement lawsuits against Pfizer and BioNTech over ...

Pfizer is undervalued, trading just over 8x 2026 earnings, with improving dividend yield and core business fundamentals.

Pfizers approaching patent cliff and expanding pipeline remain central as the pharmaceutical group advances oncology programs ...

Pfizer draws attention as healthcare steadies a mixed market, supported by oncology progress, vaccine development and ...

The two New Jersey suits assert eight patents against Pfizer and 10 against Moderna, extending existing mRNA litigation ...

U.S. drugmaker Pfizer has temporarily discontinued Premarin vaginal cream in India, shrinking estrogen therapy options for ...

It could prove to be a case of better later than never for the healthcare giant.

As Pfizer and Moderna have tied off certain threads in their separate webs of mRNA patent litigation, Sanofi has opened a new ...

McDonald's and Pfizer are blue-chip laggards trading at a discount, and both promise retirees a place to park serious money.

AZN targets continued 2026 growth with expanding blockbuster medicines, a strong pipeline and 2030 revenue goals as it ...